Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACWY-TT with or without Boostrix in healthy adolescents and young adults
2012-002737-11Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2012
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in meningococcal disease comparing Nimenrix + Boostrix with Nimenrix alone (2 arms). Primary endpoint: rSBA geometric mean titres for meningococcal serogroups A, C, W-135 and Y. Started Oct 2012; status: completed.
02
Drugs
Meningococcal polysaccharide vaccine group W-135acellular pertussis vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2012-002737-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002737-11.